AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
AIM ImmunoTech released a new CEO Corner video discussing Ampligen's potential complementary role in pancreatic cancer alongside emerging therapies like FOLFIRINOX and daraxonrasib. The segment highlights an exploratory Dutch Named Patient Program analysis in which 39 patients with NLR below 4.5 showed median overall survival of 34.8 months from the start of FOLFIRINOX, though cross-trial comparisons are not valid due to selection differences.
Key figures
- Drug Name
- Ampligen (rintatolimod)
- Phase Of Trial
- Phase 2
- Nlr threshold
- below 4.5
- Duripanc topline
- Q1 2027
- Npp patient count
- 39
- Duripanc os analysis
- Q3 2027
- Npp median os months
- 34.8
- Duripanc primary endpoint
- Clinical Benefit Rate at 24 weeks
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.